Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
WEBINAR | Join top cancer researchers to explore advances transforming early discovery, from new targets and models to the therapies of tomorrow
news

Microtitration assay developed to detect Ebola virus in vitro

Researchers have successfully created an unbiased, high-throughput microtitration assay for the quantification of Ebola virus in cell lines.

Ebola virus

In a new study, researchers have utilised a recently developed Ebola-specific reporter cell line that expresses ZsGreen in response to Ebola virus infection, in conjunction with semi-automated processing and quantification techniques, to develop an unbiased, high-throughput microtitration assay for quantification of infectious Ebola virus in vitro. The assay was developed by researchers at the US National Biodefense Analysis and Countermeasures Center and George Mason University, US. 

“The goal of the present study was to capitalise on the specificity and sensitivity afforded by this Ebola reporter cell line, while increasing the throughput of the assay to facilitate its implementation in subsequent studies,” the authors of the study write. 

According to the scientists, a variety of methods have been developed for quantification of infectious Ebola virus in clinical or laboratory samples, but existing methods often require extensive operator involvement, manual assay scoring or the use of custom reagents.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

The new assay was found to have equivalent sensitivity to a standardised plaque assay for quantifying viral titres. However, the team say the novel assay could be implemented with fewer reagents and processing steps, reduced subjectivity and higher throughput.

The researchers claim that this assay may be useful for a variety of applications, particularly studies that require the detection or quantification of infectious Ebola virus in large numbers of samples.

“By automating the dilution and read-out steps of the assay, operator involvement and subjectivity were minimised and throughput was improved,” the authors write. “This assay was compared with a plaque assay developed by FANG for quantification of filovirus virus titres. When the microtitration assay results were adjusted for the difference in units between TCID50 and PFU, the titres determined by the microtitration assay on Vero-Ebola-reporter cells were equivalent to those determined by the FANG plaque assay.”

The study was published in the Journal of Virological Methods. 

New vaccine design developed to protect against Ebola virus…